AstraZeneca Shares Jump More than 10% on U.S. Ruling

June 30, 2010
Ruling of 'valid and enforceable' patent ends three year battle with nine generic drugs manufacturers

After the company won a key U.S. ruling over its cholesterol drug Crestor, shares in Anglo-Swedish pharmaceuticals giant AstraZeneca soared by more than 10% on June 30.

The company's share price surged 10.49% to 3,256.01 pence in morning deals on the London stock market, which was showing a gain of 0.44%.

A court has ruled that AstraZeneca's patent on Crestor was "valid and enforceable", ending a three-year battle with nine generic drugs manufacturers, the group said.

Crestor generated $2.1 billion of sales in the United States last year and is a key product for AstraZeneca.

"The court's decision reaffirms the strength of the intellectual property protecting Crestor," said Chief executive David Brennan.

Copyright Agence France-Presse, 2010

Popular Sponsored Recommendations

Empowering the Modern Workforce: The Power of Connected Worker Technologies

March 1, 2024
Explore real-world strategies to boost worker safety, collaboration, training, and productivity in manufacturing. Emphasizing Industry 4.0, we'll discuss digitalization and automation...

3 Best Practices to Create a Product-Centric Competitive Advantage with PRO.FILE PLM

Jan. 25, 2024
Gain insight on best practices and strategies you need to accelerate engineering change management and reduce time to market. Register now for your opportunity to accelerate your...

Transformative Capabilities for XaaS Models in Manufacturing

Feb. 14, 2024
The manufacturing sector is undergoing a pivotal shift toward "servitization," or enhancing product offerings with services and embracing a subscription model. This transition...

Shifting Your Business from Products to Service-Based Business Models: Generating Predictable Revenues

Oct. 27, 2023
Executive summary on a recent IndustryWeek-hosted webinar sponsored by SAP

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!